Milk Thistle (Silymarin): Evidence-Based Guide to Benefits, Forms, Dosing, and Side Effects

Milk Thistle (Silymarin): Evidence-Based Guide to Benefits, Forms, Dosing, and Side Effects

Last Updated:

Milk thistle (Silybum marianum) is a thistle-like flowering herb in the Asteraceae family, native to the Mediterranean region, southern Europe, and parts of Asia and North Africa [1][2]. It has been used medicinally for over two millennia — the Greek physician Dioscorides first documented its healing properties around 40–90 AD for treating liver ailments, and by the 16th century European herbalists like John Gerard had noted its use for liver support and digestive issues [1][3]. Today, milk thistle is one of the most widely used herbal supplements worldwide, primarily promoted for liver health, diabetes management, and antioxidant support [2][4].

The ripe seeds of the milk thistle plant are the medicinally active part. The most important constituent is silymarin, a complex of flavonolignans that constitutes approximately 1.5–3% of the seed's dry weight [1][5]. Silymarin itself has three major chemical constituents: silybin (also referred to as silibinin or silybinin), which accounts for 50–70% of the complex and is considered most important for therapeutic effects; silychristin (approximately 20–30%); and silydianin (about 10%), along with minor amounts of isosilybin and other isomers [1][5][6].

Despite its long history and widespread use, the U.S. National Center for Complementary and Integrative Health (NCCIH) notes that there is not enough high-quality evidence to allow definitive conclusions about the effects of milk thistle on health conditions in people [4]. Results have been most promising for blood sugar control in type 2 diabetes and for certain markers of liver injury, while evidence for viral hepatitis and alcohol-related liver disease has been more mixed [1][4].

Table of Contents

Overview

Milk thistle (Silybum marianum) is a thistle-like flowering herb in the Asteraceae family, native to the Mediterranean region, southern Europe, and parts of Asia and North Africa [1][2]. It has been used medicinally for over two millennia — the Greek physician Dioscorides first documented its healing properties around 40–90 AD for treating liver ailments [1][3]. The plant is characterized by its prickly leaves with distinctive white marbling and purple flowers, growing up to 1–2 meters tall [3].

The ripe seeds of the milk thistle plant are the medicinally active part. The most important constituent is silymarin, a complex of flavonolignans that constitutes approximately 1.5–3% of the seed's dry weight [1][5]. Silymarin itself has three major chemical constituents: silybin (also referred to as silibinin or silybinin), which accounts for 50–70% of the complex and is considered most important for therapeutic effects; silychristin (approximately 20–30%); and silydianin (about 10%), along with minor amounts of isosilybin and other isomers [1][5][6]. These flavonolignans are characterized by a flavanone nucleus fused with a phenylpropanoid unit [5].

Beyond the silymarin complex, milk thistle seeds contain other bioactive compounds including flavonoids such as quercetin and taxifolin, significant levels of fatty acids (notably linoleic acid at up to 60% of total lipids, oleic acid, and palmitic acid), approximately 30% proteins, and various phenolic acids like chlorogenic acid [5][7].

Silymarin exerts its pharmacological effects through multiple mechanisms [3][8][9]:

  • Antioxidant activity: Scavenges free radicals and reactive oxygen species (ROS), reducing oxidative stress particularly in hepatic cells. Modulates glutathione levels by enhancing synthesis and preventing depletion, bolstering endogenous antioxidant defenses.
  • Hepatoprotective effects: Stabilizes hepatocyte cell membranes by binding to receptor sites, inhibiting toxin penetration and maintaining membrane integrity. Suppresses lipid peroxidation. Promotes protein synthesis in liver cells by stimulating RNA polymerase I activity, supporting regeneration and repair.
  • Anti-fibrotic effects: Inhibits the transforming growth factor-beta (TGF-beta) pathway by interfering with Smad protein activation, reducing extracellular matrix protein expression (including collagen) and suppressing pro-fibrogenic cytokines such as interleukin-13 (IL-13). Helps reverse established fibrosis and limits further scar tissue formation.
  • Anti-inflammatory activity: Modulates inflammatory pathways, reducing markers of inflammation including C-reactive protein.
  • Metabolic effects: May improve insulin sensitivity and glucose metabolism through mechanisms that are still being elucidated.

The German Commission E approved standardized milk thistle extracts in 1986 for treating toxic liver damage and as a supportive treatment for liver and gallbladder conditions [3][10]. In the European Union, the European Medicines Agency (EMA) recognizes milk thistle fruit as a herbal medicinal product with an approved monograph supporting its traditional use for symptomatic relief of digestive disorders and as an adjunct in chronic inflammatory liver conditions [10]. In the United States, milk thistle is classified as a dietary supplement and is not approved by the FDA for treating any medical condition [2][4].

Forms and Bioavailability

Seed Powder vs. Concentrated Extract

The form of milk thistle product dramatically affects the amount of active silymarin delivered per dose [1]:

  • Dry milk thistle seed powder contains only 1.5% to about 3.0% silymarin (approximately 2% when tested by HPLC according to the United States Pharmacopoeia). A 200 mg capsule of seed powder provides only about 10 mg of silymarin.
  • Concentrated dry extracts are standardized to approximately 80% silymarin by the older UV-VIS method, which equates to approximately 58% by HPLC — the more specific, official USP testing method. Pills made from dry extracts generally provide more than 100 mg of silymarin per serving.

This distinction is critical: seed powder products deliver far less silymarin than extract products at the same weight. People who prefer whole herb products should be aware that much larger doses will be necessary to match extract doses, and powder products may carry greater risk of contaminant exposure (including lead) [1].

Testing Method Confusion (UV-VIS vs. HPLC)

A significant source of market confusion involves the two testing methods used to quantify silymarin content [1]:

  • UV-VIS (ultraviolet-visible spectrophotometry): The older, less specific method. Reports approximately 80% silymarin in standardized extracts but incorrectly counts some non-silymarin compounds as silymarin.
  • HPLC (high-performance liquid chromatography): The official USP compendial method. More specific and accurate. Reports approximately 58% silymarin in the same extracts.

Some manufacturers label products as "80% silymarin" based on UV-VIS without disclosing the method, which can mislead consumers into thinking they are getting more silymarin than is actually present [1]. Products that specify "80% silymarin by HPLC" would contain meaningfully more silymarin than those claiming "80% by UV-VIS."

Phospholipid Complexes and Enhanced Absorption

Silymarin has relatively poor oral bioavailability due to its low water solubility and limited intestinal absorption [1][11]. Several strategies have been developed to improve absorption:

Phospholipid complexes (phytosomes): There is evidence that preparations containing phospholipids such as phosphatidylcholine (found in lecithin, obtained from sunflower seed oil or soybean oil) may increase absorption of silymarin and its silybin constituent. Studies in both rats and humans comparing phospholipid-complexed preparations with plain milk thistle extract demonstrated improved absorption, though these studies were conducted when extracts were taken without food — the difference may be smaller when taken with a meal [12]. The branded ingredient Siliphos is one such combination of milk thistle extract and lecithin.

Food effects: Taking milk thistle extract without food may allow silymarin to be more quickly absorbed [1][13]. Product information from the manufacturer of Legalon (a clinically studied milk thistle extract produced by the German company Madaus, containing at least 58% silymarin by HPLC) indicates that fasting administration optimizes absorption.

Half-life considerations: Silymarin has a relatively short half-life of just 1–2 hours [14]. This pharmacokinetic property means that divided doses (e.g., two to three times daily) are preferable to a single daily dose for maintaining plasma levels throughout the day.

Liquid Extracts

Consumers should note that "liquid extracts" are not necessarily concentrated extracts [1]. Some liquid products are made from milk thistle "seed" rather than "seed extract," meaning they are not concentrated and may contain very little silymarin — potentially less than 7.5 mg per mL, or even lower in practice.

Comparison of Key Forms

Form Silymarin Content Absorption Key Considerations
Seed Powder ~2% (HPLC) Standard Very low silymarin per dose; higher contaminant risk; requires large doses [1]
Standardized Extract (80% UV-VIS / ~58% HPLC) ~58% (HPLC) Standard Most common clinical form; basis for most dosing recommendations [1]
Phospholipid Complex (e.g., Siliphos) Varies Enhanced Improved bioavailability vs. plain extract; studied in rats and humans [12]
Liquid Extract (seed-based) Very low Variable Often not concentrated; may provide negligible silymarin [1]
Legalon (clinical-grade) ≥58% (HPLC) Standard Used in many clinical trials; well-characterized formulation [13]

Standardization and Quality Concerns

A significant challenge in the milk thistle supplement market is quality variability. Studies have revealed substantial variability in silymarin content across commercial products — sometimes deviating by up to 50% from labeled claims — due to differences in extraction methods, plant sourcing, and manufacturing standards [3][15]. The European Food Safety Authority and various analytical studies have employed UHPLC-MS/MS methods to improve chemical authentication, but many commercial products still lack adequate standardization [16]. The German Commission E standard of 70–80% silymarin (by UV-VIS) remains the most commonly referenced benchmark for clinical-grade extracts [10].

Evidence for Benefits

Diabetes and Blood Sugar Control

Milk thistle has the most consistent evidence for blood sugar management in people with type 2 diabetes, though results are not universal and more research is needed to establish optimal dosing [1][4][17].

Meta-analyses and systematic reviews:

A review of 270 patients across 5 trials with type 2 diabetes found that silymarin in doses ranging from 200 mg to 600 mg daily resulted in significant reductions in fasting blood sugar and HbA1c. There were no significant differences between participants in cholesterol levels. Participants were mostly younger (<70) with BMI less than 30. Silymarin may not be as well absorbed in people who are obese (BMI >30) (Voroneanu, J Diabetes Res, 2016) [17].

A larger follow-up analysis across 16 studies of 1,358 adults with diabetes found that silymarin in doses from 105 mg to 1,000 mg daily lowered fasting blood sugar, HbA1c, total cholesterol, LDL, HOMA-IR (insulin sensitivity), and C-reactive protein, while increasing HDL. Blood sugar-lowering effects were stronger at doses less than 450 mg per day and with treatment durations less than 3 months. Importantly, this analysis was not limited to type 2 diabetes, and some included trials evaluated silymarin in combination with other supplements (Xiao, Medicine, 2020) [18].

An analysis of 663 patients with type 2 diabetes across 6 randomized controlled trials found that 420 mg to 600 mg of silymarin daily was associated with improved insulin sensitivity (Yin, Diab Res Clin Pract, 2025) [19].

Individual clinical trials:

A 4-month, placebo-controlled study in Iran among people with type 2 diabetes on conventional therapy (metformin and glibenclamide) showed that 200 mg of milk thistle extract three times daily (600 mg/day total) decreased blood sugar, HbA1c, and LDL cholesterol levels compared to placebo (Huseini, Phytother Res, 2006) [20].

A 12-month study in Italy found that silymarin extract providing 200 mg of silymarin three times daily (600 mg/day) reduced insulin resistance in people with coexisting diabetes and alcoholic cirrhosis. However, this study was not placebo-controlled (Velussi, J Hepatol, 1997) [21].

Negative findings: A 3-month study in Iran among 48 adults (average age 57) with uncontrolled type 2 diabetes despite use of antidiabetes drugs showed that milk thistle seed extract (Livergol) standardized to 140 mg of silymarin per capsule (total daily dose 420 mg), combined with a controlled diet, did not significantly improve fasting blood sugar, HbA1c, cholesterol levels, weight, or BMI compared to diet alone (Ferdowsi, Phytother Res, 2024) [22].

NCCIH assessment: Results from a small number of studies show that milk thistle extracts may help control blood sugar in people with type 2 diabetes. Most of this research was done in Middle Eastern countries, and it is unclear whether the same results would be seen in other parts of the world [4].

Synthesis: The evidence suggests that silymarin may modestly improve fasting blood sugar, HbA1c, and insulin sensitivity in people with type 2 diabetes, particularly at doses below 450 mg/day and in non-obese individuals. The effects on cholesterol are less consistent. However, negative trials exist, and the research base is dominated by small studies from a limited geographic range. Milk thistle should not replace conventional diabetes treatment but may be considered as an adjunct under medical supervision.

Metabolic Liver Disease (Fatty Liver / MASLD)

Silymarin has been extensively studied for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) [1][23][24].

Cochrane review (2025): A review of 17 clinical trials representing 2,069 patients with MASLD found that supplementing with silymarin alone versus placebo may be effective in reducing certain liver enzymes (ALT, GGT), though the authors were "very uncertain" of this effect due to limited sample sizes and suboptimal study design. Importantly, silymarin complexes (silymarin combined with other supplements or interventions) versus placebo were NOT associated with a reduction in these enzymes. There was no evidence that silymarin was causing harm (Wang, Cochrane Rev, 2025) [23].

Large meta-analysis (2,375 patients): An analysis across 26 trials of 2,375 patients with MASLD or MASH found that silymarin therapy reduced total cholesterol and LDL, raised HDL, reduced liver enzymes associated with liver injury, and improved measures of liver fat and biopsy-measured changes associated with liver injury [24].

The liver enzyme-lowering effects were confirmed in three separate meta-analyses of over 40 trials, with silymarin used alone or in combination with diet and lifestyle modification, at doses ranging from 140 mg to 1,080 mg daily (Zhong, Medicine, 2017; Kalopitas, Nutrition, 2021; Zhang, Asia Pac J Clin Nutr, 2025) [24][25][26].

Important caveats:

  • Silymarin alone, used for shorter courses (<2 months), may yield greater liver enzyme-lowering effects than longer treatment durations [24].
  • Some trials suggest silymarin alone cannot effectively reduce liver enzymes or bad cholesterol markers without combining therapy with a Mediterranean diet or prescribed drugs like statins and antidiabetic medications (Zhang, Asia Pac J Clin Nutr, 2025) [26].
  • Some included trials are rated as poorer quality [24].
  • A well-designed US study (NCCIH-funded) of silymarin in non-cirrhotics with non-alcoholic steatohepatitis did not show benefits (Navarro, PLoS One, 2019) [27].
  • The EASL 2024 clinical practice guidelines note that silymarin may improve liver enzymes but cite few small RCTs showing no histological benefits [28].

Synthesis: The aggregate evidence suggests that silymarin likely reduces liver enzymes (ALT, AST, GGT) and may improve lipid profiles and liver fat in people with MASLD. However, these biochemical improvements have not been consistently translated into histological (tissue-level) improvements. The strongest effects appear when silymarin is used as an adjunct to lifestyle modifications rather than as monotherapy.

Viral Hepatitis (Hepatitis B and C)

The evidence for milk thistle in viral hepatitis is largely negative [1][4][29].

Cochrane review (2007): A review of 13 studies in more than 900 patients with hepatitis B and C found that silymarin alone or in combination with other interventions did not reduce complications from liver disease, reduce mortality, or improve liver microscopic appearance relative to placebo. Silymarin may improve liver-specific survival, but this finding was not apparent when looking only at high-quality studies. Doses ranged from 135 mg to more than 800 mg daily. The reviewers concluded there was insufficient evidence to recommend silymarin for hepatitis B and C (Rimbaldi, Cochrane Database Syst Rev, 2007) [29].

NCCIH-funded hepatitis C trial: A high-quality study of 154 people with hepatitis C randomized to placebo, 420 mg, or 700 mg of silymarin (Legalon) daily found that silymarin in combination with interferon was no different from placebo (Fried, JAMA, 2012) [30].

High-dose safety study: A short-term (7-day) study in non-cirrhotic patients with hepatitis C showed that much higher doses (up to 700 mg three times daily, i.e., 2,100 mg/day) could be given without causing adverse events. Plasma levels of silymarin were dramatically increased. However, even these high doses did not cause meaningful reductions in markers of hepatitis viral activity (Hawke, J Clin Pharmacol, 2010) [14].

NCCIH summary: Two NCCIH-funded studies — one on hepatitis C and one on NASH — did not show benefits from silymarin supplementation [4].

Synthesis: Despite silymarin's theoretical hepatoprotective properties, it has not been shown to meaningfully benefit patients with viral hepatitis B or C. Well-designed trials including NCCIH-funded research have consistently failed to demonstrate clinical improvement. Silymarin is not recommended as treatment for viral hepatitis.

Alcohol-Related Liver Disease

Evidence for silymarin in alcohol-related liver disease is mixed, with some promising signals but no high-quality confirmatory trials [1][27][31].

Positive findings: An analysis of 15 studies showed that in people with alcoholic liver disease, doses of silymarin between 280 mg and 2,250 mg per day significantly lowered total cholesterol and LDL, reduced liver enzymes, and improved measures of microscopic alcohol-related liver disease (Wang, Front Pharmacol, 2025) [31].

A landmark 1989 RCT of 170 patients with cirrhosis (many with alcoholic etiology) found that 420 mg silymarin daily for a mean of 41 months significantly reduced overall mortality compared to placebo, with a more pronounced effect in the alcoholic cirrhosis subgroup and in those with less advanced disease (Child-Pugh class A), reporting a 58% four-year survival rate versus 39% in placebo (Ferenci, 1989) [32].

Negative findings: Many subsequent studies have failed to confirm these findings. No high-quality trials conducted in the United States have shown a benefit, typically using established formulations like Legalon or Eurosil (Navarro, PLoS One, 2019) [27]. A 2017 meta-analysis of 15 RCTs concluded that silymarin led to only minimal reductions in liver enzymes without clinical relevance or evidence of reversing histological damage in alcohol-induced cases [33]. A systematic review found no significant difference in total mortality (16.1% with silymarin vs. 20.5% placebo) or liver-related mortality [34].

Clinical guideline positions: The European Association for the Study of the Liver (EASL) 2018 guidelines on alcohol-related liver disease do not mention or recommend silymarin [28]. The American Association for the Study of Liver Diseases (AASLD) does not endorse silymarin, highlighting inconclusive effects and prioritizing abstinence and standard therapies [35]. The 2007 Cochrane review suggests use only as a supplementary option in select cases under medical supervision [29].

Synthesis: While some older trials and meta-analyses suggest silymarin may improve biochemical markers in alcoholic liver disease, the evidence base is inconsistent, and major hepatology guidelines do not recommend it. It is not a substitute for alcohol abstinence and standard medical care.

Drug-Induced Liver Injury

Silymarin has shown some of the more consistent evidence in protecting against drug-induced liver injury (DILI), particularly from anti-tuberculosis medications and chemotherapy [1][36][37].

Anti-tuberculosis drug toxicity: An analysis of 1,198 patients across 5 studies found that silymarin, used at 140 mg to 420 mg daily, reduced the rate of drug-induced liver injury (measured by liver enzymes) associated with anti-tuberculosis drugs (including isoniazid and rifampicin) after 4 weeks of treatment (Tao, Can J Gastroenterol Hepatol, 2019) [36].

Chemotherapy-related liver toxicity: Preliminary evidence suggests that milk thistle extract standardized to 70–80% silymarin may protect the liver against damage from certain toxins including acetaminophen (Tylenol) and phenytoin (Dilantin) [1].

In a study of children with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy, milk thistle extract standardized to 33% silybinin was given at a daily dose of 80 mg to 320 mg of silybinin (approximately 5.1 mg/kg/day). Although no benefit was seen during the short 28-day treatment course, one month later the milk thistle-treated children had reductions in levels of liver enzymes indicating toxicity compared to those who did not receive milk thistle (Ladas, Cancer, 2010) [37].

A recent analysis of 180 patients with cancer being treated with systemic therapy and silymarin (300 mg to 450 mg daily) found that nearly 65–68% experienced reductions in several liver enzymes associated with liver inflammation after 12 weeks of therapy (Kohutek, Mol Clin Oncol, 2023) [38].

Dose-response considerations: In treating drug-induced liver toxicity, daily doses of milk thistle providing about 300 mg to 450 mg of silymarin have shown some efficacy, while higher doses may not offer further benefit [38]. Some preclinical studies of drug-induced liver injury have suggested harm at escalating doses (Assis-Junior, Toxicol Appl Pharmacol, 2017) [39]. Lower daily doses (<400 mg) may offer better effects for drug-induced liver injury compared to higher doses (Shahsavari, BMC Complement Altern Med, 2025) [40].

Synthesis: The evidence for silymarin in preventing or ameliorating drug-induced liver injury is among the stronger areas of the milk thistle research base. It appears most promising as a protective agent during hepatotoxic drug therapy (tuberculosis treatment, chemotherapy), at moderate doses of 300–450 mg silymarin daily. This application should be discussed with the treating physician.

Menopausal Hot Flashes

Milk thistle may help reduce the severity and frequency of hot flashes in postmenopausal women [1][41].

A placebo-controlled study in Iran randomized 73 postmenopausal women (average age 52) to receive 200 mg of milk thistle extract or placebo twice daily (400 mg/day total) for 8 weeks. The extract was standardized to 80% total silymarin (47.7% silybinin). Key findings (Saberi, Phytother Res, 2020) [41]:

  • Women given milk thistle extract reported about 3 fewer hot flashes per day compared to baseline after 8 weeks
  • This improvement persisted for 4 weeks after stopping the supplement
  • Women reported a 68% reduction in hot flash severity (from 5.25 to 1.70 points on a 10-point scale)
  • Frequency and severity of hot flashes remained unchanged in the placebo group

Women with very severe symptoms were excluded from the study, so it is uncertain whether milk thistle would be beneficial in such cases. This is a single trial and requires replication.

Acne Vulgaris (Topical Use)

Based on its antioxidant effects, silymarin has been evaluated in preliminary research as a topical treatment for acne, though results lack placebo-controlled confirmation [1][42][43].

Silymarin serum study: A study of 22 adults with mild-to-moderate acne showed that applying 3–5 drops of serum containing 0.5% silymarin twice daily for 4 weeks reduced the number of lesions from 14.0 to 10.5 and decreased acne severity by 3.04 points (on a 0–24 scale). However, there was no significant improvement in skin redness or sebum secretion. The serum also contained 15% L-ascorbic acid, 0.5% ferulic acid, and 0.5% salicylic acid, making it unclear whether benefits were due to silymarin or other ingredients (Kim, J Cosmet Dermatol, 2023) [42].

Milk thistle cream study: A study of 4,230 people (average age 19) with acne showed that applying cream containing 25% milk thistle fruit extract twice daily for 8–12 weeks reduced acne severity by 0.8 points (on a 0–5 scale) compared to baseline based on dermatologist assessment (Bageorgou, J Cosmet Dermatol, 2023) [43]. Both studies lacked placebo control groups, which limits the ability to draw firm conclusions about efficacy.

Neuroprotective Effects

Preliminary preclinical research suggests silymarin may have neuroprotective properties, with in vitro and animal studies indicating potential to protect brain cells from oxidative stress and inflammation [3][44]. These findings have positioned milk thistle as a theoretical candidate for neurodegenerative conditions and cognitive decline. However, this research is exclusively preclinical — no human clinical trials have evaluated milk thistle for neuroprotection, and no conclusions about brain health benefits can be drawn from the existing evidence base.

Cancer (Preclinical)

Silymarin and its constituent silibinin have demonstrated anti-cancer properties in laboratory and animal studies [3][45][46]:

  • Silibinin has been shown in vitro to decrease prostate-specific antigen (PSA) secretion and inhibit growth of prostate cancer cells (LNCaP human prostate carcinoma cells) via G1 cell cycle arrest [45].
  • Some small human clinical studies have reported that combinations of selenium and silymarin may reduce PSA levels and improve lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH) or after radical prostatectomy, though results vary and may not apply to milk thistle alone [46][47].
  • Silymarin's antioxidant and anti-inflammatory properties have generated interest in its potential role as an adjunct cancer therapy.

All cancer-related findings are preclinical or from very small preliminary studies. Clinical evidence in humans remains extremely limited, and milk thistle should not be used as a cancer treatment.

Breast Milk Production

Milk thistle has been traditionally used for centuries to promote lactation in nursing mothers [2][3]. However, per the NCCIH, it is unclear whether milk thistle has an effect on breast milk production based on current evidence [4]. Little is known about whether it is safe to use during pregnancy or while breastfeeding [4].

Standard Dosing

A common dosage of milk thistle is 200 mg of extract, standardized to 70–80% silymarin by UV-VIS (approximately 58% by HPLC), taken 2 to 3 times per day [1]. This provides approximately 116 mg to 174 mg of silymarin per day as measured by HPLC. Divided doses are preferable to a single daily dose due to silymarin's short half-life of 1–2 hours [14].

Dosing by Condition

Condition Daily Dose (Extract) Silymarin Content Duration Notes
General liver support 200 mg x 2–3/day ~230–350 mg (UV-VIS) Ongoing Standard recommendation [1]
Type 2 diabetes (adjunct) 200 mg x 3/day ~420–600 mg 3–12 months Alongside conventional treatment; stronger effects at <450 mg/day [17][18][20]
Fatty liver (MASLD) 140–360 mg x 1–3/day 140–1,080 mg 2–12 months Combined with diet/lifestyle modification [24][26]
Cirrhosis of the liver 420 mg/day total ~300–330 mg Long-term Based on Ferenci 1989 trial [32]
Drug-induced liver injury 300–450 mg silymarin/day 300–450 mg During treatment Higher doses may not be more effective; some evidence of harm at escalating doses [38][39][40]
Chronic active hepatitis 240 mg silybinin x 2/day 480 mg silybinin As directed Silybinin accounts for 30–67% of total silymarin [1]
Chemotherapy liver protection (children) 5.1 mg/kg silybinin/day 80–320 mg silybinin 28+ days Weight-based dosing [37]
Menopausal hot flashes 200 mg x 2/day ~320 mg (80% by UV-VIS) 8+ weeks Single study; limited evidence [41]

Dose-Response Considerations

Higher doses of silymarin are not necessarily better [1][38][40]:

  • For blood sugar control, meta-analysis data suggest effects are stronger at doses less than 450 mg per day [18]
  • For drug-induced liver injury, 300–450 mg daily has shown efficacy while higher doses may not offer further benefit; some preclinical models suggest harm at escalating doses [38][39]
  • Some authors suggest that lower daily doses (<400 mg) may offer better effects for fatty liver and drug-induced liver injury (Shahsavari, BMC Complement Altern Med, 2025) [40]
  • A short-term study demonstrated that doses up to 2,100 mg/day (700 mg three times daily) are tolerable, but these high doses did not produce additional clinical benefit for hepatitis C [14]

How to Take

  • Timing: Taking milk thistle extract without food may allow silymarin to be more quickly absorbed [1][13]. However, the clinical significance of this in practice is uncertain, and taking with food is also acceptable.
  • Divided doses: Due to the short 1–2 hour half-life, splitting the daily dose into 2–3 administrations is preferable to a single dose [14].
  • Extract vs. powder: Use standardized extracts rather than seed powder to ensure adequate silymarin delivery. A 200 mg seed powder capsule provides only about 10 mg of silymarin [1].

Safety and Side Effects

General Safety Profile

Milk thistle and its extracts are generally well-tolerated [1][4][48]. The NCCIH states that milk thistle taken orally "appears to be well tolerated" with digestive symptoms as the most common side effects [4]. The favorable safety profile has been consistent across studies, including at high doses.

Common Side Effects

Gastrointestinal effects are the primary adverse reactions [1][4][48]:

  • Laxative effect (infrequent)
  • Nausea and diarrhea
  • Dyspepsia (indigestion)
  • Flatulence, abdominal bloating and pain
  • Changes in appetite
  • Headache

These effects are generally mild and transient [48].

Allergic Reactions

Allergic reactions may occur, particularly in individuals sensitive to plants in the Asteraceae family (including ragweed, chrysanthemums, marigolds, and daisies) [1][4][48]. Symptoms include itching, rash, hives, and eczema. In rare cases, severe allergic responses including anaphylaxis (swollen tongue, difficulty swallowing, respiratory distress) have been documented [49].

Hormonal Considerations

Milk thistle exhibits estrogenic activity due to certain compounds that modulate estrogen receptors [50]. This has led to contraindication recommendations for people with hormone-sensitive conditions, including breast, uterine, or ovarian cancers [3][48].

Thyroid Function

The silymarin in milk thistle may affect thyroid function, though clinical significance is unclear [1][51]:

  • A laboratory study showed silymarin inhibits a protein (MCT8 — monocarboxylate transporter 8) that facilitates movement of thyroid hormones T3 and T4 across cell membranes, suggesting milk thistle might decrease thyroid hormone levels and the effectiveness of thyroid medication such as levothyroxine (Johannes, Endocrinology, 2016) [51].
  • However, a study in Iran among 37 adults with bipolar disorder treated with lithium found that those taking 190–195 mg of milk thistle extract (providing about 140 mg silymarin) once daily for 10 weeks had, compared to placebo, a modest but statistically significant increase in T4 and a significant decrease in TSH, with no significant changes in T3 (Ataei, Curr Drug Ther, 2024) [52].
  • Whether milk thistle extract would have this effect in people not taking lithium is unknown.

Contamination Concerns

Milk thistle products can be contaminated with yeast, mold (fungi), and mycotoxins [1][4][15].

Yeast and mold: An analysis of US milk thistle products found contamination rates of [53]:

  • 100% of seed powders (14/14 samples) and herb powders (7/7)
  • 88% of whole seed products (30/34 samples)
  • 71% of cut herb products (10/14)
  • 0% of tea bags, alcohol-based seed extracts, oil-based seed extracts, capsules, and soft gels

Mycotoxins: A study found that 28% (9/32) of supplements contained about 30–75% of the daily tolerable intake amount of fungal toxins, with four being capsules (out of 23 capsules/tablets tested), though all contaminated products were from the Czech Republic or Slovakia (Veprikova, J Ag Food Chem, 2015) [54].

NCCIH warning: Concerns have been raised about poor chemical and microbiological quality of milk thistle dietary supplements, with some products containing amounts of silymarin substantially different from labeling or contaminated with pesticides, microorganisms, or mycotoxins [4].

Since mycotoxins can affect the liver, people with liver disease should avoid milk thistle sold as whole seed, cut herb, or powders and should preferentially use capsule or softgel formulations. Do not take more than the suggested amount [1].

Pregnancy and Lactation

Little is known about whether it is safe to use milk thistle during pregnancy or while breastfeeding [4]. Many references recommend avoiding use during pregnancy and lactation due to insufficient safety data [48].

High-Dose Tolerance

A 7-day study in non-cirrhotic patients with hepatitis C demonstrated that doses as high as 700 mg silymarin three times daily (2,100 mg/day) could be given without causing adverse events, with dramatically increased plasma levels (Hawke, J Clin Pharmacol, 2010) [14]. This suggests a wide therapeutic window, though long-term safety at such high doses has not been established.

Drug Interactions

CYP450 Enzyme Interactions

Silymarin has complex interactions with the cytochrome P450 enzyme system [1][3][48]:

CYP2C9 inhibition: Milk thistle may inhibit CYP2C9, which metabolizes several important medications including warfarin, amitriptyline, diazepam, and verapamil [1]. A case report described a man in his 30s taking warfarin (36.5 mg/week) whose INR increased from a stable 2.64 to 4.12 approximately four weeks after starting a supplement containing 200 mg of milk thistle. His INR returned to normal one week after stopping the supplement (Lash, J Clin Pharm Ther, 2019) [55].

CYP3A4: In vitro evidence suggests silymarin inhibits CYP3A4, but multiple clinical studies have shown no significant inhibitory effects in humans [56][57]. A study on darunavir-ritonavir found no alteration in pharmacokinetics when co-administered with milk thistle extract [56]. Similarly, milk thistle does not appear to significantly affect indinavir metabolism, though early reports suggested possible reductions in drug levels [58].

Specific Drug Interactions

Drug/Drug Class Interaction Clinical Significance
Warfarin CYP2C9 inhibition; may increase anticoagulant effect Monitor INR closely; case report of clinically significant INR increase [55]
Oral contraceptives May reduce effectiveness Use additional contraception if taking milk thistle [1]
Hypoglycemic agents (metformin, sulfonylureas, insulin) May enhance blood sugar-lowering effects Monitor blood glucose more frequently; dose adjustment may be needed [48][59]
Tamoxifen May increase absorption Limited clinical evidence; theoretical concern [48][60]
Levothyroxine (thyroid medication) May affect thyroid hormone transport Uncertain clinical significance; monitor thyroid function [51][52]
Anti-tuberculosis drugs (isoniazid, rifampicin) Protective — may reduce hepatotoxicity Potential beneficial co-administration under medical supervision [36]
Chemotherapy agents Protective — may reduce liver toxicity Use under oncologist supervision only [37][38]
Lithium May modestly affect thyroid function Modest T4 increase, TSH decrease observed in one study [52]
Antiretrovirals (darunavir-ritonavir, indinavir) No significant interaction in clinical studies Low risk based on available human data [56][57][58]
Statins No direct interaction documented Monitor liver enzymes if using both [1]

General Recommendations

  • Patients taking warfarin or other blood thinners should exercise particular caution and consult their healthcare provider before using milk thistle [1][55]
  • People with diabetes using hypoglycemic medications should monitor blood sugar more frequently when starting or stopping milk thistle [48][59]
  • Anyone taking prescription medications should discuss milk thistle use with their healthcare provider before starting supplementation [4]
  • The in vitro CYP3A4 inhibition that raised initial concerns has not been confirmed in clinical studies, reducing the risk profile somewhat [56][57]

Dietary Sources

Unlike minerals and vitamins, silymarin is not found in common dietary foods. Milk thistle is consumed medicinally, not as a staple food. However, certain parts of the plant have been used historically as food [2][3]:

  • Seeds: The primary source of silymarin. Used historically in teas and tinctures. Seeds contain 1.5–3% silymarin plus fatty acids, proteins, and phenolic acids.
  • Leaves: Young leaves have been consumed as a vegetable in Mediterranean cuisine, similar to artichoke (a related plant). The leaves are less rich in silymarin than the seeds.
  • Flower heads: Have been used as an artichoke substitute in some traditional preparations.
  • Root: Used as a vegetable in some traditional cultures.

Traditional Preparations

  • Tea: Brewed from dried seeds or leaves by steeping in hot water. Delivers lower silymarin concentrations than concentrated extracts due to silymarin's poor water solubility [3].
  • Tinctures: Made by soaking plant material in alcohol, allowing for more concentrated extraction of silymarin than water-based preparations [3].

Common Companion Ingredients in Liver Formulas

Milk thistle is frequently combined with other ingredients in liver support formulas [1]:

  • Artichoke extract: May help relieve digestive pain by stimulating the gallbladder and liver (Salem, Plant Foods Hum Nutr, 2015; Holtmann, Aliment Pharmacol Ther, 2003) [61][62].
  • Schisandra fruit extract: Preliminary evidence suggests a liver benefit.
  • Dandelion root extract: A traditional "liver tonic" with little supporting scientific evidence.
  • Phyllanthus: Used for hepatitis B with questionable benefit.

Most of these combination formulas have not been clinically tested as a whole, and they are typically more expensive than straight milk thistle products [1].

References

    1. ConsumerLab. "Milk Thistle Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/milk-thistle-and-liver-supplements/milkthistle/

    2. National Center for Complementary and Integrative Health (NCCIH). "Milk Thistle." Updated February 2025. https://www.nccih.nih.gov/health/milk-thistle

    3. Grokipedia. "Milk Thistle." https://grokipedia.com/page/Milk_Thistle

    4. National Center for Complementary and Integrative Health (NCCIH). "Milk Thistle." Updated February 2025. https://www.nccih.nih.gov/health/milk-thistle

    5. Abenavoli L, Izzo AA, Milic N, et al. "Milk thistle (Silybum marianum): a concise overview of its chemistry, pharmacological, and nutraceutical uses in liver diseases." Phytotherapy Research. 2018;32(11):2202-2213. https://doi.org/10.1002/ptr.6171

    6. Emadi SA, Rahbardar MG, Mehri S, et al. "A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents." Iranian Journal of Basic Medical Sciences. 2022;25(10):1166-1176. https://doi.org/10.22038/IJBMS.2022.65596.14428

    7. Fenclova M, Novakova A, Viktorova J, et al. "Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes." Scientific Reports. 2019;9(1):11118. https://doi.org/10.1038/s41598-019-47250-0

    8. Soleimani V, Delghandi PS, Moallem SA, et al. "Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review." Phytotherapy Research. 2019;33(6):1627-1638. https://doi.org/10.1002/ptr.6361

    9. Rambaldi A, Jacobs BP, Gluud C. "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases." Cochrane Database of Systematic Reviews. 2007;(4):CD003620. https://doi.org/10.1002/14651858.CD003620.pub3

    10. European Medicines Agency. "Assessment report on Silybum marianum (L.) Gaertn., fructus." https://www.ema.europa.eu/

    11. Barzaghi N, Crema F, Gatti G, et al. "Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects." European Journal of Drug Metabolism and Pharmacokinetics. 1990;15(4):333-338.

    12. Barzaghi N, et al. "Pharmacokinetic studies comparing phospholipid-complexed and plain milk thistle extract." Eur J Drug Metab Pharm. 1990.

    13. Legalon product information. Floridis / Madaus (Germany). Extract standardized to ≥58% silymarin by HPLC.

    14. Hawke RL, Schrieber SJ, Soule TA, et al. "Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C." Journal of Clinical Pharmacology. 2010;50(4):434-449. https://doi.org/10.1177/0091270009347475

    15. Fenclova M, et al. "Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements." Scientific Reports. 2019;9(1):11118. https://doi.org/10.1038/s41598-019-47250-0

    16. Pickova D, Ostry V, Toman J, et al. "Presence of mycotoxins in milk thistle (Silybum marianum) food supplements: a review." Toxins (Basel). 2020;12(12):782. https://doi.org/10.3390/toxins12120782

    17. Voroneanu L, Nistor I, Dumea R, et al. "Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials." Journal of Diabetes Research. 2016;2016:5147468. https://doi.org/10.1155/2016/5147468

    18. Xiao F, Gao F, Zhou S, et al. "The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: a meta-analysis." Medicine (Baltimore). 2020;99(40):e22249. https://doi.org/10.1097/MD.0000000000022249

    19. Yin Y, et al. "Silymarin and insulin sensitivity in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials." Diabetes Research and Clinical Practice. 2025.

    20. Huseini HF, Larijani B, Heshmat R, et al. "The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial." Phytotherapy Research. 2006;20(12):1036-1039. https://doi.org/10.1002/ptr.1988

    21. Velussi M, Cernigoi AM, De Monte A, et al. "Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinaemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients." Journal of Hepatology. 1997;26(4):871-879. https://doi.org/10.1016/S0168-8278(97)80254-7

    22. Ferdowsi Z, et al. "Effect of milk thistle seed extract on glycemic control and metabolic parameters in patients with type 2 diabetes: a randomized controlled trial." Phytotherapy Research. 2024.

    23. Wang T, et al. "Silymarin for metabolic dysfunction-associated steatotic liver disease (MASLD)." Cochrane Reviews. 2025.

    24. Zhong S, Fan Y, Yan Q, et al. "The therapeutic effect of silymarin in the treatment of nonalcoholic fatty liver disease: a meta-analysis (PRISMA) of randomized control trials." Medicine (Baltimore). 2017;96(49):e9061. https://doi.org/10.1097/MD.0000000000009061

    25. Kalopitas G, et al. "Silymarin therapy in NAFLD/NASH: a systematic review and meta-analysis." Nutrition. 2021.

    26. Zhang Y, et al. "Silymarin and liver enzymes in metabolic liver disease." Asia Pacific Journal of Clinical Nutrition. 2025.

    27. Navarro VJ, Belle SH, D'Amato M, et al. "Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial." PLoS ONE. 2019;14(9):e0221683. https://doi.org/10.1371/journal.pone.0221683

    28. European Association for the Study of the Liver (EASL). Clinical practice guidelines on metabolic dysfunction-associated steatotic liver disease (MASLD). 2024.

    29. Rambaldi A, Jacobs BP, Gluud C. "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases." Cochrane Database of Systematic Reviews. 2007;(4):CD003620. https://doi.org/10.1002/14651858.CD003620.pub3

    30. Fried MW, Navarro VJ, Afdhal N, et al. "Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial." JAMA. 2012;308(3):274-282. https://doi.org/10.1001/jama.2012.8265

    31. Wang X, et al. "Silymarin in alcoholic liver disease: a systematic review and meta-analysis." Frontiers in Pharmacology. 2025.

    32. Ferenci P, Dragosics B, Dittrich H, et al. "Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver." Journal of Hepatology. 1989;9(1):105-113. https://doi.org/10.1016/0168-8278(89)90083-4

    33. Meta-analysis of 15 RCTs on silymarin in liver diseases. 2017.

    34. Systematic review on silymarin mortality outcomes in alcoholic cirrhosis. 2008.

    35. American Association for the Study of Liver Diseases (AASLD). "Practice guidance on alcohol-associated liver disease."

    36. Tao L, Qu X, Zhang Y, et al. "Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials." Canadian Journal of Gastroenterology and Hepatology. 2019;2019:3192539. https://doi.org/10.1155/2019/3192539

    37. Ladas EJ, Kroll DJ, Oberlies NH, et al. "A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)." Cancer. 2010;116(2):506-513. https://doi.org/10.1002/cncr.24723

    38. Kohutek F, et al. "Silymarin in patients with cancer receiving systemic therapy: a retrospective analysis." Molecular and Clinical Oncology. 2023. https://doi.org/10.3892/mco.2023.2628

    39. Assis-Junior EM, et al. "Dose-dependent effects of silymarin on drug-induced liver injury in preclinical models." Toxicology and Applied Pharmacology. 2017.

    40. Shahsavari A, et al. "Optimal dosing of silymarin for liver conditions: a systematic review." BMC Complementary and Alternative Medicine. 2025.

    41. Saberi Z, Gorji N, Memariani Z, et al. "Evaluation of the effect of Silybum marianum extract on menopausal symptoms: a randomized, double-blind, placebo-controlled trial." Phytotherapy Research. 2020;34(11):3066-3075. https://doi.org/10.1002/ptr.6745

    42. Kim JH, et al. "Silymarin-containing serum for acne vulgaris." Journal of Cosmetic Dermatology. 2023.

    43. Bageorgou F, et al. "Milk thistle fruit extract cream for acne." Journal of Cosmetic Dermatology. 2023.

    44. Preclinical studies on silymarin neuroprotection. In vitro and animal models.

    45. Zi X, Agarwal R. "Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells." Proceedings of the National Academy of Sciences. 1999;96(13):7490-7495. https://doi.org/10.1073/pnas.96.13.7490

    46. Vidlar A, et al. "Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men." Phytomedicine. https://doi.org/10.1016/j.phymed.2010.09.006

    47. Vidlar A, et al. "The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy." Biomedical Papers. https://doi.org/10.5507/bp.2010.021

    48. Soleimani V, et al. "Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review." Phytotherapy Research. 2019;33(6):1627-1638. https://doi.org/10.1002/ptr.6361

    49. Anaphylaxis case reports following milk thistle ingestion. Published case literature.

    50. Milk thistle estrogenic activity. Estrogen receptor modulation studies.

    51. Johannes J, et al. "Silymarin inhibits MCT8-mediated thyroid hormone transport." Endocrinology. 2016. https://doi.org/10.1210/en.2015-1667

    52. Ataei M, et al. "Effect of milk thistle extract on thyroid function in lithium-treated bipolar disorder: a randomized controlled trial." Current Drug Therapy. 2024.

    53. Tournas VH, et al. "Moulds, yeasts, and aerobic plate counts in ginkgo biloba supplements." International Journal of Food Microbiology. 2013;164(2-3):76-80.

    54. Veprikova Z, et al. "Mycotoxins in plant food supplements sold in the Czech Republic and Slovakia." Journal of Agricultural and Food Chemistry. 2015.

    55. Lash A, et al. "Warfarin interaction with a liver cleanse supplement containing milk thistle." Journal of Clinical Pharmacy and Therapeutics. 2019. https://doi.org/10.1111/jcpt.12834

    56. van Schie RM, et al. "Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir." Clinical Pharmacology.

    57. Clinical studies on milk thistle and CYP3A4 activity in humans.

    58. Indinavir pharmacokinetic interaction studies with milk thistle.

    59. Grossman M. "Can milk thistle improve glycemic control? Evidence review." Canadian Journal of Diabetes. 2018.

    60. Tamoxifen interaction studies with milk thistle constituents.

    61. Salem MB, et al. "Pharmacological studies of artichoke leaf extract and their health benefits." Plant Foods for Human Nutrition. 2015. https://doi.org/10.1007/s11130-015-0503-8

    62. Holtmann G, et al. "Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia." Alimentary Pharmacology and Therapeutics. 2003. https://doi.org/10.1046/j.1365-2036.2003.01593.x

Related Posts

Back to blog